TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Tangible Hydra-PEG: A Promising Solution for Scleral Lens Wearers With Dry Eye

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Reduced tear film break up time (TBUT), a sign of dry eye disease and contact lens discomfort~* Scleral lens wearer (at least 8 hours per day for at least 5 days per week and have had their habitual lenses no longer than 1 year). Scleral lenses wear will be defined as 15.00 mm to 19.00 mm inclusive.~Exclusion Criteria:~* Disorders that affect sensitivity (herpetic disease, severe diabetes mellitus)~* Anatomic variations of the conjunctiva that can impair proper scleral lens fitting~* Pregnancy~* Best corrected Snellen visual acuity worse than 20/30 in either eye~* Ocular pathology other than dry eye (e.g. glaucoma, macular degeneration, keratoconus) which may significantly impact visual function.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Treated followed by untreated (Type: EXPERIMENTAL): Patients wear the Hydra-PEG treated scleral lenses for 30 days. After testing and a post contact lens wear washout period, these patients will then wear the untreated lenses for 30 days. In this arm, the intervention (scleral lenses treated with Tangible Hydra-PEG) is administered prior to the control treatment (untreated scleral lenses).
- Untreated followed by treated (Type: EXPERIMENTAL): Patients wear the untreated scleral lenses for 30 days. After testing and a post contact lens wear washout period, these patients will then wear the Hydra-PEG treated lenses for 30 days. In this arm, the intervention (scleral lenses treated with Tangible Hydra-PEG) is administered after the control treatment (untreated scleral lenses).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stage IIIB or Stage IV NSCLC~* Stable disease or a clinical response following first-line treatment, consisting of either chemotherapy alone or chemotherapy and radiotherapy. Subjects must have completed the first-line treatment at least 3 weeks prior to study entry~* Eastern Cooperative Oncology Group (ECOG) performance status of greater than or equal to (\>=) 2~* Ability to understand and willingness to sign a written informed consent~* Other protocol-defined inclusion criteria could apply~Exclusion Criteria:~* Received immunotherapy within 4 weeks prior to study entry~* Received immunosuppressive drugs within 3 weeks prior to study entry~* Subjects with known brain metastases~* Past or current history of neoplasm other than lung carcinoma, except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least 5 years~* Autoimmune disease or immunodeficiency~* Clinically significant hepatic, renal or cardiac dysfunction~* Subjects with clinically significant active infection~* Pregnant or breast feeding women, women of childbearing potential, unless using effective contraception as determined by the investigator~* Other protocol-defined exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tecemotide (L-BLP25) plus Best Supportive Care (BSC) (Type: EXPERIMENTAL): None
- Best Supportive Care (BSC) Alone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting Followed by 86 Days in an Ambulatory Setting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Smoking, apparently healthy subject as judged by the Investigator.~* Subject smokes at least 10 commercially available mCCs per day (no brand restrictions) for the last 4 weeks, based on self-reporting.~* Subject has smoked for at least the last 3 consecutive years.~* Subject does not plan to quit smoking within the next 6 months.~Exclusion Criteria:~* As per Investigator judgment, the subject cannot participate in the study for any reason (e.g., medical, psychiatric, and/or social reason).~* The subject has received medication within 14 days or within 5 half-lives of the medication (whichever is longer), which has an impact on CYP1A2 or CYP2A6 activity.~* For women: Subject is pregnant or is breast feeding.~* For women: Subject does not agree to use an acceptable method of effective contraception.

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- THS 2.2 Menthol (mTHS 2.2) (Type: EXPERIMENTAL): Ad libitum use of THS 2.2 Menthol for 5 Days in a Confinement Setting and 86 Days in an Ambulatory Setting
- Menthol Conventional Cigarette (mCC) (Type: ACTIVE_COMPARATOR): Ad libitum use of subject's own preferred brand of mCC for 5 Days in a Confinement Setting and 86 Days in an Ambulatory Setting
- Smoking abstinence (SA) (Type: SHAM_COMPARATOR): Abstinence from smoking for 5 Days in a Confinement Setting and 86 Days in an Ambulatory Setting

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pentoxifylline Treatment of Acute Pancreatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Predicted Severe Acute Pancreatitis~2. Enrollment within 72 hours of diagnosis~3. Ability to give informed consent~4. Age \>17 years~Exclusion Criteria:~1. Moderate or severe congestive heart failure~2. History of seizure disorder or demyelinating disease~3. Nursing mothers~4. Pregnancy~5. History of prior tuberculosis or risk factors for tuberculosis~6. Evidence of immunosuppression (malignancy, chronic renal failure, chemotherapy within 60 days, ongoing steroid treatment\*, and HIV)- (\*the exception of prednisone use will be allowed to participate).~7. Evidence of chronic pancreatitis from history and examination (however, acute on chronic pancreatitis diagnosis is allowed)~8. Evidence of active or pending hemorrhage.~9. Paralytic ileus with vomiting

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pentoxifylline (Type: EXPERIMENTAL): Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Active, moderate to severe psoriasis defined by the following criteria: Clinically stable, plaque psoriasis involving more than 10% body surface area (BSA) or PASI 10.~* In the opinion of the investigator, failure, intolerance, contraindication or not a candidate for the following: Methotrexate (MTX), cyclosporine, and psoralen plus ultraviolet A radiation (PUVA) therapy.~* Negative urine pregnancy test before the first dose of study drug in all female patients~Exclusion Criteria:~* Evidence of skin conditions (e.g., eczema) other than psoriasis that would interfere with evaluations of the effect of study medication on psoriasis.~* Any rheumatologic disease such as rheumatoid arthritis, psoriatic arthritis, gout, systemic lupus erythematous, systemic vasculitis, scleroderma and polymyositis, or associated syndromes.~* Prior exposure to TNF inhibitors including ETN. Prior exposure to efalizumab (Raptiva®) and alefacept (Amevive®) is also prohibited.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: ACTIVE_COMPARATOR): None
- Group B (Type: EXPERIMENTAL): None
- Group C (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Study Will Evaluate the Effect of AZD9164 in Patients With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* A clinical diagnosis of COPD~* FEV1 40 - 80% of the predicted normal value (post-bronchodilator) and post- bronchodilator FEV1/FVC \< 70%~Exclusion Criteria:~* Any clinically relevant abnormal findings at screening examinations~* Any clinically significant disease or disorder

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AZD9164 100 mcg First, then Placebo for Spririva (Type: EXPERIMENTAL): 1 x AZD9164 solution for inhalation through nebulisation 100 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation
- AZD9164 400 mcg First, then Placebo for Spiriva (Type: EXPERIMENTAL): 1 x AZD9164 solution for inhalation through nebulisation 400 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation
- AZD9164 1200 mcg First, then Placebo for Spiriva (Type: EXPERIMENTAL): 1 x AZD9164 solution for inhalation through nebulisation 1200 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation
- Spiriva 18 mcg First, then Placebo for AZD9164 (Type: ACTIVE_COMPARATOR): 1 x Spiriva dry powder for inhalation 18 mcg + 1 x placebo for AZD9164 (sodium chloride)
- Placebo for Spiriva First, then Placebo for AZD9164 (Type: PLACEBO_COMPARATOR): 1 x placebo Spiriva dry powder for inhalation + 1 x placebo for AZD9164 (sodium chloride)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Zonisamide on Cocaine Reinforcement, Craving, and Relapse

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age at least 21 years old, not older than 45 years.~* Evidence of cocaine dependence.~* Not seeking treatment for cocaine abuse.~* Able and willing to be restricted to our unit for 6-7 weeks.~* Able to answer frequent questionnaires reliably and consistently.~* Smoker.~Exclusion Criteria:~* Allergy to Sulfonamide drugs (e.g. topiramate, zonisamide, sulfamethoxazole/trimethoprim).~* Diabetes, respiratory insufficiency, renal tubular acidosis or renal insufficiency, heart failure, liver insufficiency, chronic diarrhea, other chronic diseases predisposing to acidosis.~* Renal insufficiency defined as serum creatine \> 1.30 mg/DL for males or \> 1.03 mg/DL for females.~* History of nephrolithiasis, unexplained hematuria on screening urinalysis.~* History of head injury (with loss of consciousness longer than a few minutes).~* History of seizure, or use of antiepileptic medications.~* HIV positive individuals who meet AIDS by Centers for Disease Control (CDC) criteria or are on antiretroviral medications.~* BMI \< 19 or BMI \> 34.~* Total cholesterol \> 240mg%.~* Serous psychiatric illness with psychosis, dementia.~* Glaucoma, family history of glaucoma, one-sided blindness.~* For female participants: being pregnant, lactating or not using an effective method of contraception.~* Physical dependence on any drug other than cocaine, nicotine, or caffeine.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Zonisamide (Type: EXPERIMENTAL): Participants administered blind capsules containing either placebo or zonisamide.
- Placebo (Type: PLACEBO_COMPARATOR): Participants administered only placebo capsules containing lactose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have a primary diagnosis of Bipolar I Disorder, most recent episode depressed, with or without rapid cycling, without psychotic features, as defined in Diagnostic and Statistical Manual (of Mental Disorders) - Fourth Edition - Text Revision (DSM-IV-TR) (296.5X) and confirmed by a structured Mini International Neuropsychiatric Interview (MINI)~Exclusion Criteria:~* Subjects with a DSM-IV TR diagnosis of schizophrenia (295.XX), schizoaffective disorder (295.70), schizophreniform disorder (295.40), delusional disorder (297.1), or psychotic disorder not otherwise specified (298.9).~* Subjects with other DSM-IV TR Axis I or Axis II disorder (in addition to Bipolar I disorder) are ineligible if the comorbid condition is clinically unstable, requires treatment, or has been a primary focus of treatment within the 6 month period prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 20-40mg BID arm (Type: ACTIVE_COMPARATOR): None
- 60-80mg bid arm (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \>18 years affected by malignant pleural mesothelioma previously treated with no more than one systemic therapeutic regimen~* Histologically or cytological confirmed malignant pleural mesothelioma of any of the following subtype: epithelial, sarcomatous, mixed~* Prior intrapleural cytotoxic agents including bleomycin not considered systemic chemotherapy~* ECOG Performance status 0 - 2~* Adequate baseline bone marrow, hepatic and renal function, defined as follows:~  * Neutrophils \> 1.5 x 10\^9/L and platelets \> 100 x 10\^9/L~ * Bilirubin \< 1.5 x ULN~ * AST and/or ALT \< 2.5 x ULN in absence of liver metastasis~ * AST and/or ALT \< 5 x ULN in presence of liver metastasis~ * Serum creatinine \< 1.5 x ULN~* Absence of any conditions in which hypervolemia and its consequences (e.g. increased stroke volume, elevated blood pressure) or haemodilution could represent a risk for the patient (take as reference Technical data sheet human albumin specifically used in Pharmacy Department for NGR-hTNF dilution)~* Patients may have had prior therapy providing the following conditions are met:~  * Chemotherapy and radiotherapy: wash-out period of 28 days~ * Surgery: wash-out period of 14 days~* Normal cardiac function and absence of uncontrolled hypertension~* Patients must give written informed consent to participate in the study~Exclusion Criteria:~* Concurrent anticancer therapy~* Patients may not receive any other investigational agents while on study~* Clinical signs of CNS involvement~* Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol~* Known hypersensitivity/allergic reaction to human albumin preparations or to any of the excipients~* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol~* Pregnancy or lactation. Patients - both males and females - with reproductive potential (i.e. menopausal for less than 1-year and not surgically sterilized) must practice effective contraceptive measures throughout the study. Women of childbearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to registration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NGR-hTNF (Type: EXPERIMENTAL): NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion every 3 weeks or weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Prader Willi Syndrome confirmed by genetic testing (DNA methylation or FISH)~* Ages 13-20 years~* body mass index (BMI) \> 85th percentile for age and gender~Exclusion Criteria:~* Is currently using or has previously used a glucagon-like peptide-1 (GLP-1) agonist~* History of pancreatitis, or renal failure~* History of familial pancreatitis~* Amylase, or lipase levels \> 2.5 times the upper limit of normal any time in the previous 2 years~* Creatinine clearance \< 30 mL/min~* Other syndromic diagnoses~* gastrointestinal (GI) or renal illness in the 1 month prior to entering study~* Inability to take study drug~* Pregnancy~* Initiation of growth hormone (GH), estrogen, or testosterone or change \> 25% of dose/kg/day during the 6 months prior to starting study~* Non-English speaking

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide (Type: EXPERIMENTAL): All subjects enrolled in this study will be given Exenatide for 6 months. Exenatide: The investigators will give patients naive to GLP-1 agonists exenatide per manufacturer dosing recommendations for 6 months. The investigators will begin by giving 5 mcg subcutaneously twice a day for 1 month and then increase the dose to 10 mcg subcutaneously twice a day for the remainder of the study (5 months).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy infants, aged from 6 weeks through full 7 weeks,~* Consent form signed by at least one parent or by the legal representative properly informed about the study,~* Parent(s) / legal representative able to understand the protocol requirements and to fill in the Diary Card.~Exclusion Criteria:~* History of congenital abdominal disorders, congenital malformation of the gastrointestinal tract that could predispose to intussusception, or abdominal surgery,~* Congenital fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency,~* Known or suspected impairment of immunological function,~* Known hypersensitivity to any component of RotaTeq® (e.g. sucrose) or of NeisVac-C® (including tetanus toxoid),~* Prior administration of any rotavirus vaccine,~* Prior administration of any vaccine within the 28 days prior to randomisation,~* Fever (rectal temperature ≥38.1°C) and/or acute diarrhoea and/or vomiting at randomisation,~* History of known prior rotavirus gastroenteritis, chronic diarrhoea, or failure to thrive,~* Any severe thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injection,~* Clinical evidence of active gastrointestinal illness,~* Receipt of intramuscular, oral, or intravenous corticosteroid treatment within the 14 days prior to randomisation. Note: Infants on inhaled and/or topical steroids may participate in the study,~* Infants residing in a household with an immunocompromised person,~* Prior receipt of a blood transfusion or blood products, including immunoglobulins.

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 55 Days
- Healthy Volunteers: t

Study Arms:
- Group 1: Concomitant Administration (Type: EXPERIMENTAL): Participants received 2 concomitant doses of RotaTeq® and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age and a third dose of RotaTeq® at 24-25 weeks of age (and 28 to 42 days after the vaccine administration at 20-21 weeks of age).
- Group 2: Sequential Administration (Type: ACTIVE_COMPARATOR): Participants received 3 doses of RotaTeq® at 6-7 weeks of age, 15-16 weeks of age, and 24-25 weeks of age (and 28 to 42 days after the MMC vaccine administered at 20-21 weeks of age), and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete